Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (2823)	5/12/2010 12:34:51 PM
From: Jibacoa	Respond to of 3722

SCLN was up 12% and is still up 11.14% at present with volume of > 346Ks about 1/2 its ADV The stock is up for 3rd day on a roll as it faces the resistance at the $4 level.<g> bigcharts.marketwatch.com It announced last week that it will present at two upcoming investor conferences: Rodman & Renshaw Annual London Investment China Conference next Monday in London. And the Oppenheimer Annual China Dragon Call Conference on Tuesday in N.Y. SCLN main product is ZADAXIN for the treatment of hepatitis B and hepatitis C viruses, and certain cancers, as well as for use as a vaccine adjuvant or as a chemotherapy adjuvant for cancer patients with weakened immune systems. The drug has been approved in approximately 30 countries, primarily in Asia, eastern Europe, the Middle East, and Latin America, and has completed a PII for treatment of stage IV melanoma.. SCLN is also developing SCV-07, which is in a PII for treatment of oral mucositis and hepatitis C virus. It also has commercialization rights for DC Bead, a product candidate for the treatment of advanced liver cancer in China, as well as for ondansetron RapidFilm, an oral thin film formulation of ondansetron to treat and prevent nausea and vomiting caused by chemotherapy, radiotherapy, and surgery in China and Vietnam. SCLN is headquartered in Foster City, CA. SCLN has 4Qs of better revenues and earnings have improved at triple digits.<g> The EE for the current Yr, are around $0.36 and $0.45 for 2011 SCLN has no significant LTD and has +CF The short ratio increased 7% in the last month and is > 3x its ADV.<g> The ACTAY is $7.08 but I will keep a target at $6 <g> bigcharts.marketwatch.com Bernard

To: Jibacoa who wrote (2823)	5/18/2010 12:22:51 PM
From: Jibacoa	Read Replies (2) \| Respond to of 3722

CBPO opened with a small UG but found resistance again at the $14 level.<g> The stock was up 8.02% and still is up 5.63% with volume of 70Ks >1/2 its ADV bigcharts.marketwatch.com CBPO reported yesterday its 1stQ results which showed a 28% improvement in revenues and a 27% improvement on earnings. The revenues increase of 28.1% to $27.1M was mainly on account of price increase, due to the continued supply shortage in China's plasma industry. They anticipate the potential for some further price increase in the future, on select products, but have not factored that in its 2010 guidance.<g> As of March 31,CBPO had $51.2M in cash. However, the cash generated from operating activities in the Q was only $2.1M vs. $7.1M last Yr. It attributed the decline to increases in inventory and accounts receivables and higher income taxes paid.<g> CBPO's guidance for 2010 was for revenues in the range of $142 to $149M and income in the range of $34M to $36M They have applied for Human Prothrombin Complex Concentrate and Human Coagulation Factor VIII that are still under SFDA review. They expects to be able to launch these two products in late 2010 or early 2011. The ACTAY is $18.50 As mentioned, the nearest resistance is at $14 and then the May13 H at $14.32 On a close above $15 the stock would make an all time H.<g> bigcharts.marketwatch.com Bernard